137 related articles for article (PubMed ID: 36084319)
21. Computed tomography textural analysis for the differentiation of chronic lymphocytic leukemia and diffuse large B cell lymphoma of Richter syndrome.
Reinert CP; Federmann B; Hofmann J; Bösmüller H; Wirths S; Fritz J; Horger M
Eur Radiol; 2019 Dec; 29(12):6911-6921. PubMed ID: 31236702
[TBL] [Abstract][Full Text] [Related]
22. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.
Herman SE; Gordon AL; Hertlein E; Ramanunni A; Zhang X; Jaglowski S; Flynn J; Jones J; Blum KA; Buggy JJ; Hamdy A; Johnson AJ; Byrd JC
Blood; 2011 Jun; 117(23):6287-96. PubMed ID: 21422473
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological modulation of Kv1.3 potassium channel selectively triggers pathological B lymphocyte apoptosis in vivo in a genetic CLL model.
Severin F; Urbani A; Varanita T; Bachmann M; Azzolini M; Martini V; Pizzi M; Tos APD; Frezzato F; Mattarei A; Ghia P; Bertilaccio MTS; Gulbins E; Paradisi C; Zoratti M; Semenzato GC; Leanza L; Trentin L; Szabò I
J Exp Clin Cancer Res; 2022 Feb; 41(1):64. PubMed ID: 35172855
[TBL] [Abstract][Full Text] [Related]
24. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
25. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor.
Reinart N; Nguyen PH; Boucas J; Rosen N; Kvasnicka HM; Heukamp L; Rudolph C; Ristovska V; Velmans T; Mueller C; Reiners KS; von Strandmann EP; Krause G; Montesinos-Rongen M; Schlegelberger B; Herling M; Hallek M; Fingerle-Rowson G
Blood; 2013 Jan; 121(5):812-21. PubMed ID: 23118218
[TBL] [Abstract][Full Text] [Related]
26. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
[TBL] [Abstract][Full Text] [Related]
27. Novel Richter Syndrome Xenograft Models to Study Genetic Architecture, Biology, and Therapy Responses.
Vaisitti T; Braggio E; Allan JN; Arruga F; Serra S; Zamò A; Tam W; Chadburn A; Furman RR; Deaglio S
Cancer Res; 2018 Jul; 78(13):3413-3420. PubMed ID: 29735551
[TBL] [Abstract][Full Text] [Related]
28. Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia.
Rovida A; Maccalli C; Scarfò L; Dellabona P; Stamatopoulos K; Ghia P
Clin Cancer Res; 2021 Feb; 27(3):729-739. PubMed ID: 33051305
[TBL] [Abstract][Full Text] [Related]
29. Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in Eµ-TCL1 mice.
Kohlhas V; Hallek M; Nguyen PH
Blood Adv; 2020 Dec; 4(24):6106-6116. PubMed ID: 33351104
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
[TBL] [Abstract][Full Text] [Related]
31. Clonally unrelated Richter syndrome are truly de novo diffuse large B-cell lymphomas with a mutational profile reminiscent of clonally related Richter syndrome.
Favini C; Talotta D; Almasri M; Andorno A; Rasi S; Adhinaveni R; Kogila S; Awikeh B; Schipani M; Boggione P; Mouhssine S; Ghanej J; Al Essa W; Mahmoud AM; Dondolin R; Alessa N; Margiotta Casaluci G; Boldorini R; Gattei V; Gaidano G; Moia R
Br J Haematol; 2022 Sep; 198(6):1016-1022. PubMed ID: 35829664
[TBL] [Abstract][Full Text] [Related]
32. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
33. Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).
Woyach JA; Bojnik E; Ruppert AS; Stefanovski MR; Goettl VM; Smucker KA; Smith LL; Dubovsky JA; Towns WH; MacMurray J; Harrington BK; Davis ME; Gobessi S; Laurenti L; Chang BY; Buggy JJ; Efremov DG; Byrd JC; Johnson AJ
Blood; 2014 Feb; 123(8):1207-13. PubMed ID: 24311722
[TBL] [Abstract][Full Text] [Related]
34. Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice.
Tang CH; Chang S; Hashimoto A; Chen YJ; Kang CW; Mato AR; Del Valle JR; Gabrilovich DI; Hu CC
Cancer Immunol Res; 2018 Jun; 6(6):696-710. PubMed ID: 29650518
[TBL] [Abstract][Full Text] [Related]
35. The
Perez-Chacon G; Zapata JM
Front Immunol; 2021; 12():627602. PubMed ID: 33912159
[TBL] [Abstract][Full Text] [Related]
36. Chronic lymphocytic leukemia cells in a lymph node microenvironment depict molecular signature associated with an aggressive disease.
Mittal AK; Chaturvedi NK; Rai KJ; Gilling-Cutucache CE; Nordgren TM; Moragues M; Lu R; Opavsky R; Bociek GR; Weisenburger DD; Iqbal J; Joshi SS
Mol Med; 2014 Jul; 20(1):290-301. PubMed ID: 24800836
[TBL] [Abstract][Full Text] [Related]
37. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.
Wiestner A
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):125-34. PubMed ID: 25696845
[TBL] [Abstract][Full Text] [Related]
38. The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling.
Lorenzo-Herrero S; Sordo-Bahamonde C; Bretones G; Payer ÁR; González-Rodríguez AP; González-García E; Pérez-Escuredo J; Villa-Álvarez M; Núñez LE; Morís F; Gonzalez S; López-Soto A
Front Immunol; 2019; 10():2455. PubMed ID: 31681329
[TBL] [Abstract][Full Text] [Related]
39. Accelerated progression of chronic lymphocytic leukemia in Eμ-TCL1 mice expressing catalytically inactive RAG1.
Nganga VK; Palmer VL; Naushad H; Kassmeier MD; Anderson DK; Perry GA; Schabla NM; Swanson PC
Blood; 2013 May; 121(19):3855-66, S1-16. PubMed ID: 23502221
[TBL] [Abstract][Full Text] [Related]
40. T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients.
Damle RN; Temburni S; Banapour T; Paul S; Mongini PK; Allen SL; Kolitz JE; Rai KR; Chiorazzi N
Blood; 2012 Sep; 120(12):2438-49. PubMed ID: 22875913
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]